CJC-1295 No DAC is a synthetic peptide associated with scientific research into growth hormone-releasing hormone pathways. When reviewing research literature and peptide catalogues, researchers may encounter two important terms: CJC-1295 with DAC and CJC-1295 No DAC.
The distinction matters because the presence or absence of a Drug Affinity Complex (DAC) changes important characteristics of the molecule. This guide focuses specifically on CJC-1295 No DAC, the terminology surrounding it, and the factors researchers should consider when evaluating research materials.
What is CJC-1295?
CJC-1295 refers to a synthetic peptide developed in connection with research into growth hormone-releasing hormone (GHRH) signalling.
GHRH is involved in signalling pathways associated with growth hormone secretion. Synthetic analogues related to this pathway have therefore been studied experimentally to better understand receptor activity and endocrine signalling.
Importantly, researchers should pay attention to the exact compound identified in a study or product specification because the term “CJC-1295” is sometimes used broadly across materials that are not necessarily identical.
What does CJC-1295 No DAC mean?
The term No DAC indicates that the peptide does not contain the Drug Affinity Complex modification associated with the longer-duration CJC-1295 construct.
DAC was developed to promote interaction with circulating albumin and thereby alter the pharmacokinetic characteristics of the peptide.
The absence of this modification gives CJC-1295 No DAC different experimental kinetic characteristics from a DAC-containing construct.
Researchers should verify the exact molecular identity described by a supplier or publication rather than assuming that every material labelled “CJC-1295” represents the same construct.
What is DAC?
DAC stands for Drug Affinity Complex.
The modification was designed to facilitate albumin binding, which can alter how long a peptide remains present within an experimental biological system.
Consequently, the distinction between DAC and No DAC is more than a naming convention. It describes a structural difference that can influence experimental behaviour.
CJC-1295 No DAC vs CJC-1295 with DAC
The simplest way to understand the distinction is to compare the two forms directly.
| Characteristic | CJC-1295 No DAC | CJC-1295 with DAC |
|---|---|---|
| DAC modification | Absent | Present |
| Albumin-binding design | Does not contain the DAC modification | DAC is designed to facilitate albumin binding |
| Experimental kinetics | Shorter-duration profile relative to the DAC-modified construct | Modification designed to extend duration |
| Interchangeable? | No | No |
Researchers should therefore record the exact compound used when comparing results between experiments.
Why is CJC-1295 No DAC researched?
CJC-related compounds have been used experimentally to investigate aspects of GHRH receptor signalling and downstream endocrine responses.
Areas of scientific interest can include:
- GHRH receptor signalling
- Growth hormone secretory pathways
- Peptide-receptor interactions
- Structure-activity relationships
- Differences between modified and unmodified peptide constructs
- Experimental pharmacokinetics
These areas describe research contexts rather than established therapeutic indications.
Why does molecular identity matter?
Peptide research depends on knowing which molecule is actually being studied.
Small structural differences can change properties such as receptor interaction, stability and experimental kinetics. As a result, two compounds belonging to the same general research family should not automatically be treated as equivalent.
Researchers reviewing CJC-related literature should therefore pay particular attention to whether a study specifies a DAC-containing or No DAC construct.
CJC-1295 No DAC and Ipamorelin research
CJC-1295 No DAC is also encountered in research alongside Ipamorelin, another synthetic peptide investigated through a different signalling pathway.
CJC-1295 No DAC is associated with GHRH-related signalling, while Ipamorelin is investigated in relation to the growth hormone secretagogue receptor (GHSR), commonly called the ghrelin receptor.
The compounds should not be treated as the same molecule simply because they appear together in some experimental contexts. Each has its own molecular identity and mechanism of research interest.
Read our CJC-1295 No DAC and Ipamorelin research guide for a direct comparison of the two compounds.
CJC-1295 No DAC + Ipamorelin research blend
BioTide UK currently lists a CJC-1295 No DAC + Ipamorelin research blend containing:
- CJC-1295 No DAC — 5mg
- Ipamorelin — 5mg
- Total peptide content — 10mg
For a multi-component preparation, recording the amount of each individual peptide is more informative than recording the total quantity alone.
What should researchers look for when sourcing CJC-1295 No DAC?
Researchers evaluating peptide materials should consider more than the name displayed on a product listing.
1. Exact product identity
The specification should make clear which peptide or peptide combination is being supplied.
2. Quantity and composition
Where a preparation contains more than one research compound, the amount of each component should be clearly identified.
3. Batch traceability
Batch or lot identifiers allow researchers to associate materials with specific analytical documents and experimental records.
Read our guide to peptide batch testing and traceability for more information.
4. Analytical methodology
When reviewing analytical documentation, researchers should consider which methods were actually used rather than relying solely on a headline purity figure.
Methods commonly encountered in peptide analysis include High-Performance Liquid Chromatography (HPLC) and mass spectrometry.
Our HPLC vs LC-MS peptide testing guide explains how these techniques provide different types of analytical information.
5. Relevant analytical documentation
Where available, researchers should verify that a report corresponds to the relevant material and batch.
BioTide UK provides available batch-specific documentation through its analytical reports library.
What does peptide purity mean?
A reported peptide purity percentage should be interpreted according to the analytical method used.
For example, an HPLC purity result generally describes the relative contribution of a principal chromatographic component compared with other relevant detected components under the conditions of that analysis.
It should not automatically be interpreted as proving molecular identity, total peptide quantity, sterility or the percentage of total vial mass consisting of target peptide.
Read our guide to what peptide purity actually means for a detailed explanation.
A purity percentage and evidence relating to molecular identity answer different analytical questions. Researchers should review what the analytical report actually measured.
How can CJC-1295 No DAC research material be analysed?
High-Performance Liquid Chromatography
HPLC separates detectable components within a sample under defined analytical conditions.
Chromatographic analysis can provide information relevant to the relative presence of a principal component and other detectable components.
Researchers can learn how to interpret chromatograms, retention times and peak areas in our guide to reading an HPLC peptide report.
Mass spectrometry
Mass spectrometry provides information relating to the mass-to-charge characteristics of detected molecules.
This can provide evidence relevant to molecular identity when analytical observations are compared with the expected characteristics of the target peptide.
What is a peptide Certificate of Analysis?
A Certificate of Analysis (COA) can present analytical information associated with a particular sample or batch.
Depending on the testing performed, a COA may include:
- Compound identification
- Batch or sample reference
- Date of analysis
- Analytical methodology
- Reported chromatographic purity
- Chromatograms
- Mass-related analytical information
Our guide to peptide Certificates of Analysis explains how these documents can be interpreted.
Why batch-specific documentation matters
Batch-specific information improves traceability because researchers can associate an analytical report with the particular batch recorded in their experimental documentation.
An analytical result obtained from one tested sample should not automatically be treated as evidence for every future or previous batch carrying the same compound name.
Useful records may include:
- Product name
- Supplier
- Batch or lot identifier
- Quantity
- Date received
- Analytical report reference
- Relevant storage information
Maintaining these records can support experimental reproducibility and laboratory quality procedures.
Lyophilised CJC-1295 No DAC research material
Peptide research materials may be supplied in lyophilised, or freeze-dried, form where specified.
Lyophilisation is a controlled process used to remove water from frozen material primarily through sublimation.
Being lyophilised does not itself establish the purity, identity, quantity or long-term stability of a peptide.
Read our guide to what lyophilised means for more information.
Storage considerations
Storage requirements depend on the particular peptide, formulation, packaging and applicable technical documentation.
Researchers should follow the storage specifications supplied for the exact CJC-1295 No DAC research material rather than applying a universal storage rule to every peptide.
Our guide to storing lyophilised research peptides covers the main laboratory considerations.
BioTide UK CJC-1295 No DAC research materials
BioTide UK currently lists CJC-1295 No DAC within a combined laboratory research preparation containing CJC-1295 No DAC and Ipamorelin.
Researchers can review the current specification on the BioTide UK CJC-1295 No DAC 5mg + Ipamorelin 5mg research blend.
The wider range of laboratory research materials can be viewed through the BioTide UK research catalogue.
Available batch-related analytical documentation can be reviewed through the BioTide UK analytical reports library.
Frequently asked questions
What is CJC-1295 No DAC?
CJC-1295 No DAC is a synthetic research peptide associated with investigation of GHRH-related signalling and does not contain the Drug Affinity Complex modification associated with the DAC-containing construct.
What does No DAC mean in CJC-1295?
“No DAC” indicates that the peptide does not contain the Drug Affinity Complex modification associated with the longer-duration CJC-1295 construct.
Is CJC-1295 No DAC the same as CJC-1295 with DAC?
No. The presence or absence of the DAC modification represents a structural distinction that can alter experimental characteristics.
What does DAC stand for?
DAC stands for Drug Affinity Complex.
Why do researchers study CJC-1295 No DAC?
CJC-related peptides have been investigated experimentally in areas including GHRH receptor signalling, endocrine pathways, structure-activity relationships and peptide kinetics.
Is CJC-1295 No DAC the same as Ipamorelin?
No. They are distinct research peptides associated with different molecular targets and should be identified separately in experimental work.
Why are CJC-1295 No DAC and Ipamorelin researched together?
The compounds are associated with different receptor pathways within related areas of endocrine research, allowing their individual and combined experimental behaviour to be investigated.
Read our CJC-1295 No DAC and Ipamorelin guide for the full comparison.
Does high HPLC purity prove CJC-1295 No DAC identity?
Not by itself. Chromatographic purity and molecular identity are separate analytical questions and should be interpreted alongside the complete analytical documentation.
Why does the batch number matter?
A batch identifier helps researchers connect the physical research material with the analytical documentation associated with the tested sample.
Where can researchers view BioTide UK's CJC research material?
The current CJC-1295 No DAC + Ipamorelin research blend can be viewed in the BioTide UK research catalogue.
Final thoughts
CJC-1295 No DAC is a synthetic research peptide associated with investigations of GHRH-related signalling. The term “No DAC” is particularly important because it distinguishes the compound from a DAC-modified construct designed to exhibit different experimental kinetics.
For researchers, exact molecular identification, batch traceability and appropriate analytical documentation are therefore important when evaluating CJC-related materials.
Continue with our CJC-1295 No DAC and Ipamorelin research guide, learn what peptide purity means, or read why batch testing matters.
You can also browse the BioTide UK research catalogue, view the CJC-1295 No DAC + Ipamorelin research blend, or review available analytical reports.
Sources & further reading
Selected peer-reviewed literature relevant to growth hormone-releasing hormone biology, receptor signalling and the experimental investigation of synthetic GHRH analogues.
Scientific review covering GHRH biology, receptor signalling and the regulation of growth-hormone secretion.
Published investigation of CJC-1295 as a synthetic GHRH analogue and its pharmacodynamic characteristics in a controlled research setting.
Background literature relevant to GHRH-receptor function and signalling pathways used to contextualise research involving GHRH analogues.
Learn more about how BioTide UK develops and maintains educational content: BioTide UK Research Team →
Related BioTide UK resources
Continue through related research materials, analytical documentation and laboratory resources.
CJC-1295 No DAC + Ipamorelin blend →View analytical reports →Explore the research range →
